Market capitalization | $835.47m |
Enterprise Value | $198.15m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.63 |
P/S ratio (TTM) P/S ratio | 23.73 |
P/B ratio (TTM) P/B ratio | 1.22 |
Revenue growth (TTM) Revenue growth | 3,637.69% |
Revenue (TTM) Revenue | $35.21m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
11 Analysts have issued a Relay Therapeutics Inc forecast:
11 Analysts have issued a Relay Therapeutics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 35 35 |
3,646%
3,646%
|
|
Gross Profit | 30 30 |
884%
884%
|
|
EBITDA | -368 -368 |
1%
1%
|
EBIT (Operating Income) EBIT | -373 -373 |
1%
1%
|
Net Profit | -323 -323 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Sanjiv Patel |
Employees | 323 |
Founded | 2015 |
Website | www.relaytx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.